Paroxetine

Generic Name: Paroxetine

Brand Names: Paxil, Pexeva

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀FNO_₃

CAS Number: 61869-08-7

Unique Ingredient Identifier: 41VRH5220H

Background: Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...

Indication: Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...

Associated Conditions: Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

Anxiety Disorders and Depression Treatment Market to Reach

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.

clinicaltrialsarena.com

2 months ago

Supernus' depression drug improved symptoms in two hours in Phase IIa study

Supernus Pharmaceuticals' SPN-820 showed rapid and substantial effects in a Phase IIa trial for major depressive disorder, with a clinically meaningful improvement on the HAM-D6 scale and a significant reduction in suicidal ideation. SPN-820 is designed as a rapid-acting treatment, contrasting with the slower effects of SSRIs, and is well-tolerated with common AEs like headache and nausea. A Phase IIb study is ongoing, with results expected in H1 2025.

Related Clinical Trials:

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

insideprecisionmedicine.com

3 months ago

Psilocybin Provides Comparable Long-Term Antidepressant Effects as SSRIs

A study at ECNP Congress in Milan found psilocybin, from 'magic mushrooms,' as effective as escitalopram in treating depression, with potential long-term benefits. Psilocybin users reported better psychosocial functioning and life meaning over six months. Psilocybin could offer an alternative for non-responders to SSRIs, though its use requires controlled environments.

drugs.com

3 months ago

Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression

Psilocybin, in magic mushrooms, shows similar depression relief to SSRI antidepressants like Lexapro, with additional long-term benefits of greater life meaning and psychological connectedness, according to a clinical trial. However, psilocybin is experimental and should not be self-administered.

eurekalert.org

3 months ago

Study shows psychedelic drug psilocybin gives

Psilocybin and SSRI escitalopram showed similar long-term depression symptom improvements, but psilocybin offered additional benefits in psychosocial functioning, meaning in life, and psychological connectedness over 6 months. Psilocybin also improved sexual drive, unlike SSRIs, suggesting potential additional mental health benefits.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy